谷歌浏览器插件
订阅小程序
在清言上使用

The Combination of Rituximab, Plasmapheresis, Intravenous Immunoglobulins and Pre-Transplant Immunosuppression is an Effective Desensitization Strategy for Patients with Sickle Cell Disease and High Donor Specific Anti-Human Leukocyte Antigen Titer Undergoing Haploidentical Bone Marrow Transplant

Transplantation and cellular therapy(2023)

引用 0|浏览23
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要